It is made available under a CC-BY 4.0 International license.

1

1 Neonatal outcomes after proteomic biomarker-guided intervention: the AVERT

2 PRETERM TRIAL

3

- 4 Matthew K. HOFFMAN, MD, MPH¹; Carrie KITTO¹; Zugui ZHANG, PhD¹; Jing SHI²,
- 5 PhD; Michael G. WALKER², PhD; Babak SHAHBABA³, PhD; Kelly RUHSTALLER, MD
- 6 $MSCE¹$
- 7 ¹Department of Obstetrics and Gynecology, ChristianaCare, Newark, DE
- 8 ²Walker Bioscience, Carlsbad, CA
- 9 ³Departments of Statistics and Computer Science, University of California Irvine, Irvine,

10 CA

11

12 Conflicts of Interest

- 13 BS, JS, and MGW are paid consultants of Sera Prognostics, Inc. For the purposes of
- 14 this study, JS and MGW reported to MKH and were paid consultants of ChristianaCare,
- 15 and BS was supported by Sera Prognostics, Inc. MKH received an investigator-initiated
- 16 grant from Sera Prognostics, Inc., to conduct this study.

17

18 Source of Funding

- 19 This study was performed as an investigator-initiated trial funded by Sera Prognostics,
- 20 Inc. The funder provided testing and funds to conduct the trial. The study plan was

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

- 21 mutually agreed upon by the investigators and the funder; however, the funder was
- 22 blinded to study results until after data lock and analysis completion.

- 24 Corresponding Author
- 25 Matthew K. Hoffman, MD MPH
- 26 Department of Obstetrics & Gynecology
- 27 4755 Ogletown-Stanton Road
- 28 Newark, DE 19718
- 29 Telephone: +1 (302) 301-3350
- 30 Fax: +1 (302) 733-3340
- 31 Email: mhoffman@christianacare.org

It is made available under a CC-BY 4.0 International license.

32 Abstract

33 1. Background

34 Vaginal progesterone, low dose aspirin and care management (comprising increased 35 outreach and education) has been shown to reduce the rate of prematurity in select

36 populations, but identifying at-risk pregnancies has been problematic.

37 2. Objective(s)

38 Test the hypothesis that screening singleton, non-anomalous pregnancies lacking

39 traditional clinical risk factors with a validated blood test for preterm birth risk prediction,

40 then targeting those with elevated risk for preventive treatment, would improve neonatal

41 outcomes as compared to a large historical population.

42 3. Study Design

43 The AVERT PRETERM trial took place from June 2018-September 2020 at 44 ChristianaCare Hospital (Newark, DE). Singleton non-anomalous pregnancies with no 45 history of preterm birth were enrolled in a prospective study arm and followed through 46 neonatal hospital discharge. Participants were screened using a serum proteomic test 47 for spontaneous preterm birth risk during a gestational age window spanning $19^{1/7}$ -20^{6/7} 48 weeks. Pregnancies identified by the test to be at elevated risk for preterm birth 49 (≥16.0%, approximately twice the U.S. population risk) were offered aspirin 81 mg daily, 50 open-label vaginal progesterone 200 mg daily and care management. We compared 51 outcomes for women who screened either low-risk or higher-risk accepting treatment 52 with those in a historical study arm of 10,000 pregnancies. Our co-primary outcomes 53 were neonatal hospital length of stay and an ordinal neonatal morbidity index score

4

54 based on the occurrence of grade III/IV interventricular hemorrhage, necrotizing 55 enterocolitis (Bell stage II/III), respiratory distress syndrome, bronchopulmonary 56 dysplasia, retinopathy of prematurity (stage III), sepsis, and neonatal death or neonatal 57 intensive care unit length of stay. Cox proportional hazards survival analysis and ordinal 58 logistic regression were utilized to evaluate outcomes and control for population 59 differences.

60 4. Results

61 A total of 1463 women were screened and tested before research operations were 62 ceased due to the advent of the COVID-19 pandemic, and three women were 63 subsequently deemed ineligible after screening. Of these, 34.72% (507/1460) were 64 deemed high-risk, with 56.41% (286/507) accepting intervention and 43.59% (221/507) 65 forgoing intervention. The remaining 65.3% (953/1460) were designated as low-risk. 66 Women in the prospective arm were older, more obese, more likely to have 67 hypertension and smoke, and less likely to use opioids compared to women in the 68 historical arm. The primary analyses found that neonates in the prospective arm were 69 discharged from the hospital earlier $(P=0.01)$; hazard ratio, 1.35; 95% confidence 70 interval, 1.08-1.70) and had lower neonatal morbidity index scores (P=0.031; odds ratio, 71 0.81; 95% confidence interval, 0.67-0.98). Average neonatal hospital length of stay 72 decreased by 21%, and severe neonatal morbidity (neonatal morbidity index ≥3) was 73 reduced on average by 18%.

74 5. Conclusions

81 Keywords

- 82 Care management, low-dose aspirin, neonatal morbidity index, NICU length of stay,
- 83 pregnancy, preterm birth, proteomic biomarker, risk stratification, spontaneous preterm
- 84 birth, vaginal progesterone

It is made available under a CC-BY 4.0 International license.

85 Introduction

86 Preterm birth (PTB) remains the leading cause of perinatal mortality, $1,2$ and 87 children born prematurely are at greater risk for chronic medical conditions^{3,4} and 88 developmental delays.⁵ These risks are inversely proportional to the neonate's 89 gestational age (GA) at birth.⁶ Improvements in survival are largely attributable to the 90 $\;$ use of improved neonatal care⁷ and antenatal corticosteroids. 8 Strategies targeting at-91 risk women, such as focused care management 9 (comprising increased outreach and 92 education) along with low-dose aspirin (LDASA),¹⁰ and vaginal progesterone^{11,12} have 93 demonstrated reductions in PTB, but their impact has been limited by poor precision in 94 identifying at-risk pregnancies. Shortened cervical length measured by transvaginal 95 sonography in the second trimester has been shown to predict the risk of preterm 96 delivery.¹³ With vaginal progesterone treatment, the PTB rate <34 weeks' gestation is 97 decreased by approximately 45%, but the rate of PTB <37 weeks' gestation is 98 unchanged.¹⁴ The utility of this strategy is blunted by the limited ability of cervical 99 sonography to identify women who will deliver preterm, with most women delivering 100 prematurely not having a short cervix at the time of routine sonography.^{15,16} Similarly, 101 LDASA has been shown to decrease PTB incidence and severity $17,18$ but generally has 102 been recommended for pregnancies at risk for preeclampsia.¹⁹ Finally, care 103 management of higher-risk pregnancies has been shown to decrease PTB; historically, 104 however, its use has targeted pregnancies with known PTB risk factors, $9,20$ which are 105 frequently absent in those who deliver prematurely.

106 Recently, novel discoveries in proteomics have come to identify and validate 107 proteins that are differentially expressed in pregnancies that deliver prematurely

7

125 Materials and Methods

126 The AVERT PRETERM trial was conducted from June 2018-September 2020 at 127 ChristianaCare Hospital, a regional health care system based in Newark, DE. 128 ChristianaCare serves a mixed urban and rural population across Delaware and 129 Maryland.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

8

130

131 Trial Oversight

132 The study protocol (NCT03151330) was approved by the ChristianaCare institutional 133 review board prior to participant enrollment. An independent data safety monitoring 134 board convened prior to study initiation, approved the protocol, and provided oversight 135 of adverse events. All subjects provided written informed consent to participate in the 136 study. The listed authors accept responsibility for the accuracy and completeness of the 137 data and for fidelity in the conduct of the trial.

138 In April 2020, all non-COVID research was halted at ChristianaCare Health 139 System, and the decision was made to terminate the trial and reassess the analytic plan 140 in a blinded fashion. In July 2020, an investigation²³ showed that COVID-19 infection led 141 to an increase in prematurity. To avoid bias in comparison of pre-pandemic controls to 142 prospective subjects who reached term during the pandemic period, we modified the 143 statistical analysis plan (SAP), while blinded, by limiting the primary analysis to subjects 144 who had reached 37 weeks' gestation before the local spread of SARS-CoV-2 and the 145 associated research shutdown.

146

147 Screening and Recruitment

148 Two separate study arms were defined, both of which comprised singleton pregnancies 149 without ultrasound evidence of mullerian or fetal anomalies, cervical shortening (<25 150 mm), genetic anomalies, history of a prior PTB, cervical cerclage or medical conditions 151 with clear indication for PTB <37 weeks' gestation. Pregnancies in the prospective arm

9

152 were identified and screened for eligibility in ambulatory sites and/or at the time of 153 routine imaging ultrasound. Due to the requirements of the proteomic blood test for 154 prematurity (PreTRM), women in the prospective arm were excluded if they had a blood 155 transfusion during the current pregnancy, known hyperbilirubinemia, or were taking 156 traditional or low molecular weight heparin. Similarly, prospective patients were 157 excluded if they had a known reaction or contraindication to progesterone or aspirin.

158

159 Procedures

160 Following consent, blood was obtained from women in the prospective arm during the 161 window of $19^{1/7}-20^{6/7}$ weeks' gestation. Samples were processed, shipped, stored, and 162 analyzed using the PreTRM test in a Clinical Laboratory Improvement Amendments-163 and College of American Pathologists-certified laboratory (Sera Prognostics, Inc., Salt 164 Lake City, UT), as described previously.^{21,24} Test results were shared with the 165 participant and her care provider. Pregnancies with a sPTB risk score ≥16.0% 166 (approximately twice the U.S. population risk) were then offered and consented again to 167 receive care management, consisting of twice-weekly nursing contacts to monitor 168 medication compliance and symptom development, aspirin 81 mg daily, and 169 progesterone 200 mg intravaginally daily. The remainder of care was determined by the 170 treating clinician. Outcomes for both study arms were obtained through a validated 171 obstetrical registry²⁵ or, for patients in the prospective arm who delivered at another 172 institution, through review of individual medical records. External data review was 173 performed for all prospective patients in addition to 10% of the historical arm to ensure 174 that eligibility requirements were met. An error rate of <3% was deemed acceptable. All

10

175 PTB cases in both arms were reviewed further for accurate assessment of primary 176 outcomes by a single investigator (MKH). Additionally, because secular changes in care 177 might affect outcomes in a non-random fashion amongst women in the prospective arm, 178 major changes in guidance or management protocols were documented on a quarterly 179 basis.

180

181 Trial Outcomes

182 Two co-primary outcomes were selected, the first being neonatal hospital length of stay 183 (NNLOS). Because of the competing risk of death resulting in shorter stays, we set the 184 NNLOS for fetuses or newborns who expired to be one day longer than the longest 185 neonatal stay observed among all neonates. The second co-primary outcome was 186 based on a neonatal morbidity index $(NMI)^{14}$ composed of the following components: 187 grade III/IV intraventricular hemorrhage, necrotizing enterocolitis (Bell stage II/III), 188 respiratory distress, bronchopulmonary dysplasia (need for oxygen at 28 days of life or 189 36 weeks post-conceptional age), retinopathy of prematurity (stage III), proven sepsis 190 (positive blood cultures) and postnatal death. To provide severity estimates, NMI 191 scoring was organized as follows: 0, no events; 1, one event or neonatal intensive care 192 unit (NICU) admission <5 days with no perinatal mortality; 2, two events or five to 20 193 days of NICU admission with no perinatal mortality; 3, three events or >20 days in the 194 NICU without perinatal mortality; and 4, perinatal mortality.

195

196 Power and Sample Size Analysis

11

197 At termination, 1873 eligible subjects had been enrolled in the prospective arm, with 198 1460 reaching 37 weeks' gestation prior to the first reported COVID-19 case in 199 Delaware. A total of 10000 consecutive historical controls who met the same eligibility 200 criteria were selected from an approximately two-year period immediately prior to study 201 initiation.

202 From institutional data on pregnancies at ChristianaCare, we estimated a 203 historical PTB rate of 9.1%. Sample size estimation was based on simulations of the co-204 primary outcomes using a simulated GA distribution with a singleton PTB rate of 9.1% 205 and an effect of intervention based on existing literature. α-level spending of 0.05 was 206 shared between co-primaries using Holm's method.

207 For the first co-primary outcome, the proportion of subjects with NMI scores ≥3 208 was assumed to be 2.0-2.3% in the prospective arm and near 3.6% in the control arm, 209 based on a previous clinical utility study.²⁶ Assuming these proportions and a one-sided 210 Fisher's Exact test, a sample size of approximately 1453 subjects with outcomes in the 211 prospective arm with 55% compliance among higher-risk subjects, and approximately 212 10000 historical controls, would provide power of 0.7-0.9.²⁷

213 For the second co-primary outcome, NNLOS from time of birth up to discharge, 214 the hazard ratio (HR) based on simulations was expected to be 1.32-1.46, based on the 215 previously referenced clinical utility study.²⁶ Assuming these HRs, a sample size of 216 approximately 1453 subjects with outcomes in the prospective arm with 55% 217 compliance among higher-risk subjects and approximately 10000 historical controls, 218 would provide power of at least 0.8^{27}

It is made available under a CC-BY 4.0 International license.

12

219

220 Statistical Analysis

It is made available under a CC-BY 4.0 International license.

241 historical control arm (7.1%). This was done to examine outcomes at the extremes of 242 PTB rather than capturing short NICU stays for conditions that tend to dominate NICU 243 admissions, including transient tachypnea of the newborn, hypoglycemia and 244 temperature instability.

245 As prespecified in the SAP, the covariates included in the models for the primary 246 and secondary analyses were maternal age, parity and maternal substance use 247 disorders, assessed as Neonatal Opioid Withdrawal Syndrome. Additional covariates 248 were examined in sensitivity analyses.

249 Differences between the treatment arms in the proportion of each treatment 250 group at each NMI level were calculated using the fitted ordinal logistic regression 251 model with the covariates maternal age, parity and maternal substance use disorders. 252 Percent differences between the treatment arms for time to event analyses were 253 calculated using the hazard rate for each group as estimated by the fitted Cox 254 proportional hazards model with the covariates maternal age, parity and maternal 255 substance use disorders.

256 The proportional odds assumption for the effect of treatment arm in the ordinal 257 logistic regression was examined and found not to be violated. The proportional hazards 258 assumption for treatment arm in the Cox regression analyses was tested and found not 259 to be violated.

260 Analyses were performed using R software version 4.2.2.³² Two-tailed P-values 261 <0.05 were considered significant. Holm's multiple comparisons correction was used for 262 the co-primary hypotheses.

It is made available under a CC-BY 4.0 International license.

263

264 Results

- 265 At study termination, 1873 eligible subjects had been enrolled in the prospective arm,
- 266 1463 of whom aligned with pre-COVID-19 patient care conditions and were screened
- 267 with the PreTRM test (Figure 1). Of these, 34.7% (507/1463) were deemed higher risk
- 268 by the PreTRM test. Among the screened population, 83.3% (1218/1463) had clinical
- 269 outcomes and qualified either as low-risk (77.1%; 939/1218) or as higher-risk accepting
- 270 treatment (22.9%; 279/1218).

271 Baseline participant characteristics and delivery data are shown in Table 1. The 272 prospective arm was noted to be significantly older, more obese, less likely to be 273 nulliparous, and more likely to have hypertension and smoke than historical controls. 274 Similarly, body mass index was higher in the prospective arm compared to historical 275 controls – mostly due to higher weight, though the prospective arm was nominally taller 276 than historical controls. The proportion of Black women in both arms was 26.5%, 277 reflecting the racial diversity in the study site's patient population. Three women 278 reported stopping vaginal progesterone due to adverse effects, and one woman 279 discontinued LDASA.

280 Results of hypothesis tests for the co-primary and co-secondary outcomes are 281 presented in Table 2. NNLOS was significantly reduced in the prospective arm vs the 282 historical arm (HR 1.35; 95% CI, 1.08-1.7; P=0.01). The Kaplan-Meier plot for NNLOS is 283 shown in Figure 2, reflecting a reduction of mean NNLOS of 21% (Cox proportional 284 hazard [PH] $P = 0.01$). NMI scores were significantly reduced in the prospective arm vs

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

16

308 CI, 1.08-1.22, $P< 0.001$), with and without the adjustment for neonatal death,

- 309 respectively.
- 310
- 311 Comment
- 312 Principal Findings
- 313 The results of this trial demonstrate that women who were screened and stratified with a
- 314 proteomic test for PTB risk, and were treated with care management, LDASA, and
- 315 vaginal progesterone, had shorter NNLOS and less severe neonatal morbidities
- 316 compared to a large historical arm, after controlling for population differences.

317

318 Results in the Context of What is Known

319 Historically, evidence has existed for the benefit of intervening on pregnant women 320 stratified by clinical risk factors. These data suggest that proteomic biomarker-based 321 stratification and focused intervention may improve outcomes in otherwise low-risk 322 women.

323

324 Clinical Implications

325 These findings suggest a potential approach for universal screening and treatment to 326 help ameliorate complications of PTB amongst women who lack traditional risk factors 327 for preterm delivery. The results of this study resonate with an investigation³³ that 328 randomized 1,191 women to either knowing and receiving treatment vs not knowing the

17

329 results of their screening test. In that study, the NICU length of stay due to sPTB was 330 significantly less amongst those screened and treated vs. those not receiving their test 331 results (median 6.8 days vs. 45.5 days; $P=0.005$), though the study was limited by small 332 numbers. We note that similar strategies of both evaluating prior pregnancy for PTB 333 and/or routine cervical length have been widely accepted in many centers, $28,29$ but this 334 strategy captures a limited number of PTBs, and pregnancy history is not relevant for 335 the first-time mothers who represent a sizable portion of the population. 336 Given the notable increase in PTB rate among Black women (14.4%) as 337 compared to the U.S. population as a whole (10.2%) ,² it is important to note that Black 338 participants were represented in the AVERT PRETERM prospective and historical arms 339 with a proportion (26.5%) nearly double recent U.S. population estimates (13.6%).³⁰ The 340 results in this study population, along with those in two large and similarly diverse 341 studies, $21,31$ indicate that the PreTRM test will be applicable across the diverse U.S. 342 population.

343

344 Research Implications

345 Patient knowledge of preterm birth risk via validated proteomic testing may offer 346 an opportunity to combine a novel risk assessment with strategies proven to be effective 347 with clinical risk factors. Based on survey data, pregnant women are frequently resistant 348 to taking medication due to perceived deleterious effects during pregnancy. Prospective 349 trials randomizing women to being informed of results with clinical treatment vs testing 350 with blinded results have begun and will provide more definitive evidence.

It is made available under a CC-BY 4.0 International license.

18

351

352 Strengths and Limitations

353 Strengths of the trial include a multimodal strategy incorporating interventions that have 354 consistently shown benefit in reducing the impacts of prematurity, as well as a novel 355 proteomic blood test that has been validated in multiple cohorts. Additionally, we note 356 that the dataset used to obtain the historical controls has been well validated, and all 357 cases of PTB were reviewed. Clinically, the impact appears to be greatest amongst 358 pregnancies delivering <34 weeks' gestation, which remains the primary driver of 359 newborn and child morbidity and mortality.

360 Limitations of the study are inherent in the design of comparing a prospective 361 arm that differed from the historical arm in several maternal demographic and medical 362 conditions. These were addressed through multivariable modeling, but we note that this 363 remains a potential source of bias. Even so, significant demographic differences in the 364 prospective arm vs the historical arm – older age, more hypertension and more smoking 365 – likely biases the prospective arm toward increased PTB incidence, further 366 underscoring the importance of our findings. Additionally, at least for the use of LDASA, 367 guideline changes have expanded the number of women eligible for treatment, and a 368 recent estimate suggests that most pregnancies should be counseled about LDASA.³⁸. 369 Finally, we note some overlap of our co-primary outcomes, as NICULOS was also part 370 of the NMI.

371

372 Conclusions

It is made available under a CC-BY 4.0 International license.

- 373 In summary, (1) screening singleton, non-anomalous pregnancies lacking traditional
- 374 clinical risk factors with a validated proteomic blood test for preterm birth prediction,
- 375 then (2) targeting those with elevated risk for preventive treatment, improved neonatal
- 376 outcomes as compared to a large historical population. This test-and-treatment strategy
- 377 led to shorter hospital stays and improved NMI scores across a diverse population.
- 378

379 Acknowledgements

- 380 We wish to acknowledge the funding provided by Sera Prognostics, Inc., to conduct this
- 381 independent investigation. Jennifer Logan, PhD, an employee of Sera Prognostics, Inc.,
- 382 provided medical writing support for the manuscript.

383 References

- 384 1. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5
- 385 mortality in 2000-15: an updated systematic analysis with implications for the
- 386 Sustainable Development Goals. Lancet 2016;388(10063):3027-3035. DOI:
- 387 10.1016/S0140-6736(16)31593-8.
- 388 2. Osterman MJK, Hamilton BE, Martin, J.A., Driscoll AKV, C.P. Births: Final Data
- 389 for 2020. Division of Vital Statistics, National Center for Health Statistics, U.S.
- 390 Centers for Disease Control and Prevention. 2022 Feb 7. Available at
- 391 https://www.cdc.gov/nchs/nvss/births.htm. Accessed February 9, 2022.
- 392 3. Moster D, Lie RT, Markestad T. Long-term medical and social consequences of
- 393 preterm birth. N Engl J Med 2008;359(3):262-73. DOI:
- 394 10.1056/NEJMoa0706475.
- 395 4. Crump C, Sundquist K, Sundquist J, Winkleby MA. Gestational age at birth and 396 mortality in young adulthood. JAMA 2011;306(11):1233-40. DOI:
- 397 10.1001/jama.2011.1331.
- 398 5. Sun BZ, Moster D, Harmon QE, Wilcox AJ. Association of Preeclampsia in Term
- 399 Births With Neurodevelopmental Disorders in Offspring. JAMA Psychiatry

400 2020;77(8):823-829. DOI: 10.1001/jamapsychiatry.2020.0306.

- 401 6. Tyson JE, Parikh NA, Langer J, Green C, Higgins RD, National Institute of Child
- 402 H, Human Development Neonatal Research N. Intensive care for extreme
- 403 prematurity--moving beyond gestational age. N Engl J Med 2008;358(16):1672-
- 404 81. DOI: 10.1056/NEJMoa073059.

- 405 7. Richardson DK, Gray JE, Gortmaker SL, Goldmann DA, Pursley DM, McCormick
- 406 MC. Declining severity adjusted mortality: evidence of improving neonatal
- 407 intensive care. Pediatrics 1998;102(4 Pt 1):893-9. DOI: 10.1542/peds.102.4.893.
- 408 8. Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized
- 409 trials, 1972 to 1994. Am J Obstet Gynecol 1995;173(1):322-35. DOI:
- 410 10.1016/0002-9378(95)90222-8.
- 411 9. Garite TJ, Manuck TA. Should case management be considered a component of
- 412 obstetrical interventions for pregnancies at risk of preterm birth? Am J Obstet

413 Gynecol 2023;228(4):430-437. DOI: 10.1016/j.ajog.2022.09.022.

- 414 10. Hoffman MK, Goudar SS, Kodkany BS, et al. Low-dose aspirin for the prevention
- 415 of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN):
- 416 a randomised, double-blind, placebo-controlled trial. Lancet

417 2020;395(10220):285-293. DOI: 10.1016/S0140-6736(19)32973-3.

- 418 11. Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the
- 419 rate of preterm birth in women with a sonographic short cervix: a multicenter,
- 420 randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol
- 421 2011;38(1):18-31. DOI: 10.1002/uog.9017.
- 422 12. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH, Fetal Medicine
- 423 Foundation Second Trimester Screening G. Progesterone and the risk of preterm
- 424 birth among women with a short cervix. N Engl J Med 2007;357(5):462-9. DOI:
- 425 10.1056/NEJMoa067815.
- 426 13. Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of 427 spontaneous premature delivery. National Institute of Child Health and Human

It is made available under a CC-BY 4.0 International license.

- 429 1996;334(9):567-72. DOI: 10.1056/NEJM199602293340904.
- 430 14. Cahill AG, Odibo AO, Caughey AB, Stamilio DM, Hassan SS, Macones GA,
- 431 Romero R. Universal cervical length screening and treatment with vaginal
- 432 progesterone to prevent preterm birth: a decision and economic analysis. Am J
- 433 Obstet Gynecol 2010;202(6):548 e1-8. DOI: 10.1016/j.ajog.2009.12.005.
- 434 15. Esplin MS, Elovitz MA, Iams JD, et al. Predictive Accuracy of Serial Transvaginal
- 435 Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for
- 436 Spontaneous Preterm Birth Among Nulliparous Women. Jama
- 437 2017;317(10):1047-1056. DOI: 10.1001/jama.2017.1373.
- 438 16. Berghella V, Saccone G. Cervical assessment by ultrasound for preventing
- 439 preterm delivery. Cochrane Database Syst Rev 2019;9(9):CD007235. DOI:
- 440 10.1002/14651858.CD007235.pub4.
- 441 17. Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for
- 442 preventing pre-eclampsia and its complications. Cochrane Database Syst Rev

443 2019;2019(10). DOI: 10.1002/14651858.CD004659.pub3.

- 444 18. Low dose aspirin in pregnancy and early childhood development: follow up of the
- 445 collaborative low dose aspirin study in pregnancy. CLASP collaborative group. Br
- 446 J Obstet Gynaecol 1995;102(11):861-8. DOI: 10.1111/j.1471-
- 447 0528.1995.tb10872.x.
- 448 19. Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use to
- 449 Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence

It is made available under a CC-BY 4.0 International license.

471 10.1016/j.ajog.2010.06.058.

- 472 26. Branch DW, VanBuren JM, Porter TF, et al. Prediction and Prevention of Preterm
- 473 Birth: A Prospective, Randomized Intervention Trial. Am J Perinatol 2021. DOI:
- 474 10.1055/s-0041-1732339.
- 475 27. NCSS Statistical Software. Group-Sequential Analysis for Two Proportions.
- 476 Available at https://www.ncss.com/wp-
- 477 content/themes/ncss/pdf/Procedures/NCSS/Group-
- 478 Sequential Analysis for Two Proportions.pdf. Accessed May 1, 2023.
- 479 28. Son M, Grobman WA, Ayala NK, Miller ES. A universal mid-trimester
- 480 transvaginal cervical length screening program and its associated reduced
- 481 preterm birth rate. Am J Obstet Gynecol 2016;214(3):365 e1-5. DOI:
- 482 10.1016/j.ajog.2015.12.020.
- 483 29. Werner EF, Hamel MS, Orzechowski K, Berghella V, Thung SF. Cost-
- 484 effectiveness of transvaginal ultrasound cervical length screening in singletons
- 485 without a prior preterm birth: an update. Am J Obstet Gynecol 2015;213(4):554
- 486 e1-6. DOI: 10.1016/j.ajog.2015.06.020.
- 487 30. U.S. Census Bureau. Quick Facts. Available at
- 488 https://www.census.gov/quickfacts/fact/table/US/PST045222. Accessed July 18,
- 489 2023.
- 490 31. Markenson GR, Saade GR, Laurent LC, et al. Performance of a proteomic
- 491 preterm delivery predictor in a large independent prospective cohort. Am J
- 492 Obstet Gynecol MFM 2020;2(3):100140. DOI: 10.1016/j.ajogmf.2020.100140.
- 493

25

494 Table 1. Baseline characteristics and delivery data

495 †P-value reflects comparison of prospective vs historical arm.

496 *‡Race is based on self-report.*

497 BMI, body mass index.

498 Table 2: Results of hypothesis tests for the co-primary and co-secondary

499 outcomes using prespecified covariates

500 The co-primary and co-secondary outcomes included subjects in the upper 8.5%

501 quantile of neonatal length of stay, neonatal morbidity index score, and neonatal

502 intensive care unit length of stay within each arm, so that the large proportion of normal

503 births would not dilute the differences between arms.

- 504 †Cox regression analysis
- 505 ‡Ordinal logistic regression analysis

Figure 1. Consort diagram for study inclusion

509 Figure 2: Kaplan-Meier curves for neonatal hospital length of stay

511 Figure 3: Kaplan-Meier curves for gestational age (weeks) for babies born <32

512 weeks' gestation

Figure 4: Kaplan-Meier curves for neonatal length of hospital stay (days) for

babies born <32 weeks' gestation

518 Supplementary Table 1. Comparison of probabilities of NMI levels and percent

519 differences in probabilities between arms for a range of co-variate values.

NMI, neonatal morbidity index